Bookmarks
The impact of systemic corticosteroids on major adverse cardiovascular events, solid-tumours and mortality in adults: a retrospective cohort study.
Safe People
Organisation name
Pharmatelligence Ltd
Organisation sector
Commercial
Applicant name(s)
Craig Currie - Chief Investigator - Pharmatelligence LimitedBenjamin Heywood - Corresponding Applicant - Pharmatelligence LimitedSara Jenkins-Jones - Collaborator - Pharmatelligence LimitedThomas Berni - Collaborator - Pharmatelligence Limited
Safe Projects
Project ID
CPRD459
Lay summary
Corticosteroids (CS) are common treatments for managing inflammation, but there are limitations to its use. Even though they are commonly used, we don’t really have a clear understanding about the association of use of the drug with the risks of major adverse cardiovascular events (MACE), solid-tumours or mortality.
Technical summary
Systemic corticosteroids (CS) are important for managing inflammation, but there are limitations to its use. Few consistent data exist describing the association of CS and risks of major adverse cardiovascular events (MACE), solid-tumours or mortality.
Latest approval date
31/03/2021
Safe Data
Dataset(s) name
HES Admitted Patient Care
ONS Death Registration Data
Patient Level Index of Multiple Deprivation
Safe Setting
Access type
Release